Tumor CD155 Drives Resistance to Immunotherapy by Downregulating the Activating Receptor CD226 in CD8 <sup>+</sup> T Cells
Matthias Braun(QIMR Berghofer Medical Research Institute), Tobias Bald(QIMR Berghofer Medical Research Institute), Sophie Krumeich(QIMR Berghofer Medical Research Institute), Michael Hölzel(University of Bonn), Amelia Roman Aguilera(QIMR Berghofer Medical Research Institute), Ailin Lepletier(Griffith University), Dillon Corvino(University of Bonn), André Veillette(Montreal Clinical Research Institute), Ludovic Martinet(Centre National de la Recherche Scientifique), Jason Madore(QIMR Berghofer Medical Research Institute), Frank Vari(The University of Queensland), William C. Dougall(Queensland University of Technology), Ashmitha Sundarrajan(QIMR Berghofer Medical Research Institute), Gabrielle Kelly(Griffith University), Eun Young Seo(Dong-A University), Touraj Taheri(The University of Queensland), Kyohei Nakamura(QIMR Berghofer Medical Research Institute), Mark J. Smyth(Peter MacCallum Cancer Centre), Sally‐Ann Pearson(QIMR Berghofer Medical Research Institute), Georgina V. Long(The University of Sydney), Martin Batstone(Queensland Health), Sébastien Jacquelin(The University of Queensland), Richard A. Scolyer(The University of Sydney), Robert J. Johnston(Johns Hopkins University), Indrajit Das(QIMR Berghofer Medical Research Institute), Mika Casey(QIMR Berghofer Medical Research Institute), Maike Effern(University of Bonn), James S. Wilmott(The University of Sydney)
Cited by 3
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k